AntriaBio Announces First Patient Dosed in Phase 1 Clinical Study of AB101
25 juil. 2017 08h00 HE
|
AntriaBio, Inc.
LOUISVILLE, CO--(Marketwired - July 25, 2017) - AntriaBio, Inc. ("AntriaBio or the "Company") (OTCQB: ANTB), a biopharmaceutical company specializing in the development of innovative drug therapies...
AntriaBio Announces $13 Million Close of Private Placement Transaction and Plan to Dose First Patient with AB101 This Month
17 juil. 2017 08h00 HE
|
AntriaBio, Inc.
LOUISVILLE, CO--(Marketwired - July 17, 2017) - AntriaBio, Inc. ("AntriaBio or the "Company") (OTCQB: ANTB), a clinical stage biopharmaceutical company specializing in the development of...
AntriaBio Files Investigational New Drug Application for Once-Weekly Basal Insulin AB101
05 juin 2017 08h00 HE
|
AntriaBio, Inc.
LOUISVILLE, CO--(Marketwired - June 05, 2017) - AntriaBio, Inc. ("AntriaBio or the "Company") (OTCQB: ANTB), a biopharmaceutical company specializing in the development of innovative drug therapies...
AntriaBio Formally Engages CRO for the Conduct of its Phase I First-in-Human Clinical Trial of AB101
01 mai 2017 08h00 HE
|
AntriaBio, Inc.
LOUISVILLE, CO--(Marketwired - May 01, 2017) - AntriaBio, Inc. ("AntriaBio or the "Company") (OTCQB: ANTB), a biopharmaceutical company specializing in the development of innovative drug therapies...
AntriaBio Announces Offer to Amend Warrants to Purchase Shares of Common Stock
15 déc. 2016 17h15 HE
|
AntriaBio, Inc.
LOUISVILLE, CO--(Marketwired - December 15, 2016) - AntriaBio, Inc. ("AntriaBio" or the "Company") (OTCQB: ANTB), a biopharmaceutical corporation focused on developing novel extended release...
AntriaBio Announces Formation of Subsidiary and Plan to Raise Capital in South Korea
22 sept. 2016 08h00 HE
|
AntriaBio, Inc.
LOUISVILLE, CO--(Marketwired - September 22, 2016) - AntriaBio, Inc. ("AntriaBio" or the "Company") (OTCQB: ANTB), a biopharmaceutical corporation focused on developing novel extended release...
AntriaBio Announces $12 Million Private Placement
29 juin 2016 08h00 HE
|
AntriaBio, Inc.
LOUISVILLE, CO--(Marketwired - June 29, 2016) - AntriaBio, Inc. ("AntriaBio" or the "Company") (OTCQB: ANTB), a biopharmaceutical corporation focused on developing novel extended release therapies,...
AntriaBio Announces Preclinical Proof of Concept for Once-Weekly Basal Insulin AB101 in Diabetic Miniature Swine
22 juin 2016 08h00 HE
|
AntriaBio, Inc.
LOUISVILLE, CO--(Marketwired - June 22, 2016) - AntriaBio, Inc. ("AntriaBio" or the "Company") (OTCQB: ANTB), a biopharmaceutical corporation developing novel extended release therapies, released...
AntriaBio Announces Appointment of Michael Deperro as Vice President of Operations
06 janv. 2016 08h30 HE
|
AntriaBio, Inc.
LOUISVILLE, CO--(Marketwired - January 06, 2016) -
AntriaBio, Inc. ("AntriaBio" or the "Company")
(OTCQB: ANTB), a biopharmaceutical corporation developing novel extended release...
AntriaBio Announces First Close of Private Placement Transaction
10 déc. 2015 12h50 HE
|
AntriaBio, Inc.
LOUISVILLE, CO--(Marketwired - December 10, 2015) - AntriaBio, Inc. ("AntriaBio" or the "Company") (OTCQB: ANTB), a biopharmaceutical corporation developing novel extended release therapies,...